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Running title: Neuromuscular electrophysiological characteristics in men 
 
Abstract 
Background. 
The purpose of this study was to determine whether neuromuscular electrophysiological 
characteristics that are known to underlie sarcopenia are also associated with the more complex frailty 
syndrome.  
Methods 
Eighty-six men (mean (SD) age 74 (8) years) were classed as non-frail (robust), pre-frail or frail using 
criteria from the frailty phenotype (FP) and the frailty index (FI). The femoral nerve was maximally 
stimulated and the resulting compound muscle action potential amplitude (CMAP) was measured over 
the vastus lateralis (VL). Motor unit potential (MUP) size was assessed during voluntary contractions 
using intramuscular electromyography (iEMG). Logistic and negative binomial regression models 
determined relationships between FP and FI with CMAP and MUP sizes before and after adjustments 
for age and body mass index (BMI).  
Results 
Larger CMAP size was associated with a lower likelihood of frailty in fully adjusted models: a 1 
standard deviation higher level in VL CMAP size was associated with a 0.4 (95% CI: 0.2-0.6, p<0.01) 
unit lower FI (40% of the FI range) and more than halving of the odds (OR: 0.43 (0.21-0.90)) of 
having a frail/pre-frail phenotype. Greater MUP size was also related to lower FI values using 
unadjusted and fully adjusted models. However, MUP size was not significantly related to FP in any 
model.  
Conclusion 
Smaller MUPs and a smaller CMAP were significantly associated with a higher likelihood of frailty, 
independent of age and BMI. These results relate neuromuscular electrophysiological characteristics 
to the complex frailty syndrome and identify motor unit remodelling as a possible contributing factor.  
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What is the central question of this study? 
Human frailty is characterised by accumulated health complaints, including medical conditions, low 
physical and psychological function, as well as social components. It is currently unknown whether 
the condition is associated with neuromuscular changes detectable by electrophysiology obtained 
from voluntary and involuntary muscle contractions. 
 
What is the main finding and its importance? 
A higher likelihood of frailty was significantly associated with a smaller size of vastus lateralis motor 
unit potentials during voluntary contractions and smaller compound muscle action potentials 
generated by electrical stimulation. Importantly these associations were independent of age and BMI.  
 
Introduction 
 
Frailty is a major health, social and economic issue, especially in ageing populations with extended 
life expectancy. It is a leading cause of falls, fractures, immobility and loss of independence which 
results in increased healthcare costs and a higher risk of mortality (Fried et al., 2001; Zaslavsky et al., 
2013). Frailty is most commonly classified by one, or both, of two sets of criteria: one based on the 
accumulation of deficits including medical conditions, physical function, psychological and social 
components to produce a “Frailty Index” (Rockwood et al., 2005); and the other based on body size 
and physical function to give a ‘Frailty Phenotype’ (Fried et al., 2001). 
The major impacts of frailty are low physiological reserve and low physical function. These features 
are similar to those of sarcopenia and the main convergence of these two syndromes is on muscle 
mass and function (Cesari et al., 2014). It follows therefore that underlying causes of sarcopenia 
might also contribute to frailty. Sarcopenia is due to a decrease in the cross sectional area (atrophy) of 
individual muscle fibres and a decrease in the numbers of muscle fibres (Mcphee et al., 2018; 
Wilkinson et al., 2018). These muscle changes are associated with declining numbers of motor 
neurons and functioning motor units (MUs) (Piasecki et al., 2016b, 2016c, 2016a). A commonly used 
technique of assessing MU structure and function in humans is intramuscular electromyography 
(iEMG), which enables the detection and characterisation of individual motor unit potentials (MUPs) 
(Piasecki et al., 2018a). This technique was used recently to show that sarcopenic individuals have 
smaller MUPs during voluntary muscle contractions and a smaller compound muscle action potential 
(CMAP) after transcutaneous electrical stimulation of the innervating nerve compared with healthy 
older adults (Piasecki et al., 2018b). Electrophysiological characteristics such as the MUP and CMAP 
are often used to detect peripheral nerve disease progression (Maathuis et al., 2013) because their 
utility is related more broadly to the neuromuscular system rather than being limited to sarcopenia. It 
remains unknown whether such MU changes occur with the progression of frailty.  
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Since low muscle mass and weakness are defining features of sarcopenia and also core components of 
the frailty phenotype, we hypothesised that a small CMAP and/or MUPs would be associated with the 
more complex frailty syndrome. It is important to determine the causes of muscle deficits in frailty 
because they can contribute to slowness, low physical activity levels and perceptions of fatigue within 
the definition of the frailty phenotype (Fried et al., 2001) and they represent potentially modifiable 
components in the manifestation of frailty. Therefore, we aimed to determine the association between 
electrophysiological characteristics of MUs in a large limb muscle (CMAP and MUPs) and the frailty 
phenotype and frailty index measures in older men.  
 
Methods 
Ethical approval 
Ethical approval for the study was obtained from the National Research Ethics Service Committee 
Northwest (15/NW/0426) and conformed to the standards set by the latest Declaration of Helsinki, 
except for registration in a database. Written informed consent was obtained from each participant. 
All volunteers were living independently, but still the capacity of the frail older adults to consent was 
assessed by a single clinician experienced in general and geriatric medicine. This process considered 
volunteers’ ability to comprehend, retain and weigh up the information provided and screening for the 
exclusion criteria.  
 
Participants 
A total of 114 men aged 65-90 years were recruited from the Greater Manchester area between 2014-
2016. The participants were recruited from the local universities’ databases, National Health Service 
general practices and secondary care, including outpatient departments, day hospitals and community 
physiotherapy centres. The study was also made open to the general public through poster and 
newspaper advertisements. Only men were recruited to avoid the additional confounding factors of 
sex differences in muscle size, differences in fluctuating hormones known to influence muscle 
plasticity, such as androgens, and sex differences in subcutaneous adipose tissue thickness that would 
affect CMAP signal attenuation. Exclusion criteria included: individuals who lack capacity to consent 
for the study and comply with the protocol (including those who have a legal guardian); body mass 
index (BMI) < 18 kg m
-2
 or >35 kg m
-2
; history of cachexia or malnutrition; institutionalised (e.g. 
living in a nursing home); presence of co-morbidity [specifically: neurological disorders (stroke 
resulting in reduced mobility, Parkinson’s disease, dementia, motor neuron disease); cancer diagnosis 
(excluding non-fatal cancers, e.g. skin cancer, stable prostate cancer, and other stable cancers with a 
good prognosis); communicable disease such as HIV/AIDS or hepatitis; heart failure (breathless at 
rest or when walking < 100 m); NYHA III or IV]; permanent pacemaker in situ (an exclusion for 
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magnetic resonance scanning only); implantable cardioverter-defibrillator (ICD) in situ; myocardial 
infarction within the last 6 months, uncontrolled angina, peripheral arterial disease (if this limits 
function to walking < 100 m), deep vein thrombosis within the last 3 months; severe chronic 
obstructive pulmonary disease or asthma (causing shortness of breath after a few minutes of walking 
or with changing clothing (MRC shortness of breath scale grades 4 or 5); coagulation disorder or use 
of anticoagulants (e.g. warfarin, sinthrome, dabigatran, rivaroxaban, apixaban, low-molecular-weight 
heparin) that could cause excessive bleeding or bruising; lower limb or vertebral fracture within the 
previous year; hip/knee and/or spinal stenosis surgery during the last 12 months; physical limitation 
and pain due to conditions that conflict with study procedures; amputation of part of a lower limb; and 
non-fluent speakers of the English language]. 
The participants completed questionnaires, physical tests, neuromuscular assessments, 
magnetic resonance and dual-energy X-ray absorptiometry imaging.  
 
Assessments  
 
Questionnaires  
Each participant completed a questionnaire on health, lifestyle and medical history including 
medication. 
 
Anthropometry measures 
Body mass (kg) and height (m) were measured using calibrated scales and stadiometry. Total body 
composition was assessed by dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy Advance, 
version EnCore 10.50.086) with participants lying supine with legs and arms fully extended. 
Appendicular lean mass with appendicular bone mineral content (BMC) removed was normalised to 
height (Piasecki et al., 2018b). 
 
Assessment of physical function, activity and frailty 
Physical function was assessed objectively using the Short Physical Performance Battery (SPPB) 
which included an assessment of four-meter walking speed, standing balance and chair stands. The 
‘Timed up and go’ (TUG) was also performed, where participants were invited to stand from a seated 
position and walk 3 metres forward around a cone as quickly as possible, returning to their original 
seating position. The time from the command “three, two, one, go” until the participant returned to his 
seated position was recorded.  
Grip strength was measured using a handgrip dynamometer (JAMAR).  Participants were 
instructed to squeeze the handle as hard as possible for 3 seconds and the maximum contraction force 
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(in kg) was recorded. This was repeated twice for each hand, alternating between right and left with 
30 seconds rest between trials. 
 
Frailty measures 
Frailty was characterised by the two commonly used approaches: the frailty phenotype (FP) and the 
frailty index (FI).  
We adapted the FP from the Cardiovascular Health Study (Fried et al., 2001) based on five 
criteria: sarcopenia (appendicular lean mass/(height)
2  7.26 kg/m2), exhaustion (answer "most of the 
time" or "a moderate amount of time" to question “I felt that everything I did was an effort” or "I 
could not get going”), slowness (4 metre walk: slowest 20% by height), weakness (grip strength: 
lowest 20% by BMI)  and low activity (< 150 mins/week spent on physical activity). Individuals 
meeting one or more of these criteria were classed as either ‘frail’ or ‘pre-frail’ (combined as a group) 
and those with none of these criteria were classed as ‘robust’. This was done because of the relatively 
small number of men in the frail category leading to a limited ability to adjust regression models for 
relevant covariates. 
The FI comprised 37 health deficits (symptoms and signs, functional impairments) which 
accumulate with age and are associated with adverse health outcomes. The deficit variables were 
derived from questionnaire data as well as scores from physical performance tests and self-reported 
co-morbidities. The FI was created using a standardised procedure (Searle et al., 2008) and calculated 
as a ratio between number of deficits present in an individual to total number of deficits possible. 
Binary variables were coded as 0 or 1 in the case of absence or presence of a deficit, respectively. The 
intermediate response (e.g. sometimes/maybe) was coded with a value of 0.5. Continuous variables 
were dichotomised based on the distribution of participants’ scores; cut-off points were set at the 
worst performing 10
th
 centile. Individuals with over 20% of missing data on relevant deficits were 
excluded from the analysis.  
 
Electromyography (EMG) 
All EMG data were collected from around the motor point of the VL which was identified as the area 
of muscle providing the largest twitch from a percutaneous electrical stimulus applied by a cathode 
probe at 400 V, pulse width of 50 μs and current of around 8 mA, (DS7AH Digitimer, Welwyn 
Garden City, Hertfordshire, UK). A self-adhesive anode electrode (Dermatrode, Farmadomo, NL) 
was placed over the right gluteus. The motor point was typically located around 210-220 mm from the 
lateral femoral condyle, central on the transverse plain.  
The CMAP was recorded at the VL motor point by surface EMG after percutaneous femoral 
nerve stimulation. With the anode remaining on the right gluteus, the cathode was placed over the 
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femoral nerve approximately halfway between the anterior superior iliac spine and the pubis tubercle, 
proximal to the groin crease. The stimulator was set at 400 V with 50 μs pulse width and the current 
was increased through successive stimulations until the recorded potential (M-wave) plateaued, at 
which point the current was increased by approximately 30 mA to ensure supramaximal stimulation 
for the CMAP (usually at 100-150 mA). The reference electrode was placed over the patella tendon 
(disposable self-adhering Ag-AgCl electrodes; 95mm
2
, Ambu
 
Neuroline, Baltorpbakken, Ballerup, 
Denmark) and a common ground was placed over the patella (Ambu Neuroline Ground). 
MUPs were recorded using a 25 mm disposable concentric needle electrode with a recording 
area of 0.07 mm
2 
(Model N53153; Teca, Hawthorne, NY, USA). The same ground electrode was 
shared with the surface EMG. All iEMG signals were sampled at 25 kHz and bandpass filtered at 10 
Hz to 10 kHz (CED 1902 amplifier; Cambridge Electronics Design Ltd). With the participant sitting 
relaxed, the needle electrode was inserted into the VL muscle at the motor point to a depth of around 
1-2 cm. The participant then performed a sustained voluntary isometric contraction at 25% of their 
maximum effort and held it for 12-15 seconds with real time feedback from a visual display. The 
needle was positioned to ensure sharp rise times of potentials. In between contractions the needle was 
repositioned using combinations of 180-degree needle rotations and needle withdrawals of around 3 
mm. This was repeated until a minimum of six recordings from spatially distinct areas had been 
obtained.  
 
EMG analysis 
All CMAP and MUP data were recorded using Spike2 software (Version 8.1, Cambridge Electronic 
Designs) and stored for offline analysis. The amplitude (size) of the CMAP was defined as the 
amplitude of the negative peak (upward deflection) of the M-wave. Intramuscular EMG signals were 
decomposed using custom written DQEMG software (Stashuk, 1999; Piasecki et al., 2016c, 2018a). 
Individual MUPs were isolated and MUP area (size) was taken as the total area under the curve within 
the MUP duration, as previously described (Piasecki et al., 2016c). The MUPs sampled from any 
single participant were collated to calculate the mean MUP size for that individual. A minimum of 8 
MUPs per participant were required for inclusion for further analysis.  
 
Statistical analysis 
Descriptive statistics are presented as the mean ± standard deviation (SD) or n (%). Statistical 
significance of between-group differences was assessed using analysis of variance. 
Frailty phenotype models: For the purpose of analysis, individuals who were pre-frail or frail 
were combined in a single frail/pre-frail group. Logistic regression models were fitted to determine 
relationships between each predictor (MUP or CMAP) and binary outcome (frail/pre-frail vs. robust). 
Each predictor was considered as an untransformed value standardised as a Z score [(raw score – 
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mean)/standard deviation] to allow comparison of results between the predictors. The models were 
then further adjusted for age and body mass index as these were significantly correlated with the 
predictors. The results were displayed as odds ratios (OR with 95% confidence intervals) for prevalent 
frailty associated with z-score differences in either MUP or CMAP predictors.  
Frailty index models: In view of the significant right skewing of the FI variable (a count 
variable), the relationship between MUP or CMAP predictors and FI was assessed using a negative 
binomial regression model. The FI variable was rescaled and converted to a 0-37 count scale where 
‘0’ represented no deficits and ‘37’ represented the maximum number of deficits. As in the FP 
analysis, predictor variables in this model were also standardised as Z-scores and presented as 
standardised beta coefficients with 95% confidence intervals. The models were adjusted for age and 
BMI.  
To assess whether the associations between CMAP and MUP predictors with frailty phenotype were 
different in prefrail and frail men, we performed an exploratory multinomial regression analysis using 
a 3-tier (robust, prefrail, frail) FP as an outcome. 
All analyses were performed using STATA 13 SE software (StataCorp. 2013. Stata Statistical 
Software: Release 13. College Station, TX: StataCorp LP). 
 
Results 
Out of 114 men who participated in the study, 86 with complete data necessary to determine frailty 
phenotype and frailty index remained in the analytical sample (Table 1). The clinical characteristics of 
participants who remained in the study were not significantly different compared to those who were 
excluded (n=28) apart from a higher prevalence of smoking in excluded participants.  
The mean (SD) age of the men was 74 (6) years and BMI 26.1 (4.0) kg/m
2
. The prevalence of 
cardiovascular disease was 22% and diabetes 14%. There was a low prevalence of smoking (5%) and 
over half of the participants were taking three or more medications for medical conditions (the most 
common groups of drugs being statins, antiplatelets and proton pump inhibitors) (Table 1). 
The mean (range) frailty index was 0.18 (0–0.69). Classifying participants according to frailty 
phenotype identified 28 as robust, 40 as pre-frail and 18 as frail.  
Motor unit potential and CMAP data are available for 74 and 79 of the participants, 
respectively. The mean (SD) number of MUPs sampled was 20 (9) per participant. The mean MUP 
size was 1445 (706) µVms and the CMAP amplitude was 6946 (2781) µV. Men in the lowest tertile 
of MUP size (having the smallest MUPs) were older and more likely to be smokers and to have 
cardiovascular disease compared to participants with larger MUPs (Table 2). Men in the lowest tertile 
of CMAP size were older and had higher BMI and a higher prevalence of CVD and diabetes 
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compared with those with larger CMAPs (Table 2). Representative images of CMAPs and MUPs are 
shown in Figure 1. 
 Multivariate regression analysis showed that higher CMAP size was associated with a lower 
likelihood of frailty as assessed by both frailty phenotype and frailty index in models with, and 
without, adjusting for age and BMI (Table 3). For example, in fully adjusted models, a 1 SD higher 
level in VL CMAP size was associated with a 0.4 unit lower FI (40% of the full FI range) and more 
than halving of the odds (OR: 0.43) of having a frail/pre-frail phenotype.  
Similarly, higher MUP size was also related to lower frailty index values in unadjusted and 
fully adjusted models. However, higher MUP size was not significantly related to frailty phenotype in 
any model (Table 3).  
Further adjustment for diabetes did not significantly alter the results (data not shown).In the 
secondary analysis applying frailty phenotype, we found that MUP size was negatively related to risk 
of frailty but not prefrailty. This association was independent of age, BMI and diabetes when entered 
individually. CMAP size was negatively related to risk of frailty in all models, whereas the 
association with prefrailty was significant only in unadjusted and BMI adjusted models (Table 4).  
We also observed significant differences in MUP size and CMAP across frailty categories (Table 5). 
 
Discussion 
 
This study presents two novel findings. First, frail older men defined by both the frailty index 
and the frailty phenotype were more likely to have a smaller electrically-evoked CMAP. Secondly, 
frail older men defined by the frailty index were more likely to have smaller MUPs during voluntary 
muscle contractions held at 25% MVC. These significant relationships were independent of the 
possible confounders of age and BMI. Our observations relate frailty to distinct neuromuscular 
electrophysiological characteristics. Secondary analysis suggested that smaller MUPs are features of 
frailty but not prefrailty, as assessed by FP. 
The maximal CMAP represents the summation of all action potentials from all muscle fibres 
within the recording range of the surface electrode after being activated at the same time. Age-related 
decreases in CMAP size have been reported for a number of muscles, including the VL (Piasecki et 
al., 2016c, 2019), tibialis anterior (McNeil et al., 2005; Piasecki et al., 2016a), biceps brachii (Power 
et al., 2012) and soleus (Dalton et al., 2008) based on comparisons of young and old participants. 
Although CMAP size invariably decreases with advancing older age, the association between CMAP 
size and frailty is not simply explained by ageing per se because it remained significant after adjusting 
for age. Interestingly, CMAP size has been used to track clinical progression of motor neuron or 
muscle disorders, including ALS (Mori et al., 2016) and spinal muscular atrophy (Lewelt et al., 
2010), but we show that it has the potential to provide novel insights into the multi-morbidity frailty 
syndrome defined by a progressive loss of physiological reserve. Clearly, the CMAP measured after 
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stimulation of a peripheral motor nerve to induce muscle excitation is directly related to transmission 
along the nerve axons and at the neuromuscular junctions, and transmission along muscle fibres. As 
this pathway defines peripheral control of muscle contractions, CMAP size was expected to be 
associated with the frailty phenotype which strongly considers physical function (Fried et al., 2001). 
The fact that CMAP size was also associated with the frailty index, which sums a number of 
clinically-relevant ‘deficits’ (Searle et al., 2008), may reflect more broadly a range of morbidities 
common to the criteria used to determine the frailty index and frailty phenotype.  
CMAPs are relatively easy to measure, but their limitation is that they provide relatively little 
information about the extent of changes to MU number or sizes. Motor unit numbers decline with 
advancing older age and some of the surviving MUs increase in size to compensate (Hepple & Rice, 
2016; Piasecki et al., 2016b). However, we recently showed that the expansion of MU size was absent 
in people with clinically-relevant low muscle mass and weakness (sarcopenia) (Piasecki et al., 
2018b). This finding is extended in the present study beyond sarcopenia by showing that smaller 
MUPs, indicative of smaller MUs (Zalewska & Hausmanowa-Petrusewicz, 1999), are related to the 
complex condition of the frailty syndrome assessed by the frailty index. The failure to expand MU 
size in frailty may be due to low physical activity levels or to an unfavourable nerve or muscle tissue 
milieu that does not support reinnervation because of chronic low-grade inflammation, oxidative 
stress, or changing hormone levels (Hepple & Rice, 2016; Wilkinson et al., 2018), but very little is 
currently known about these mechanisms.  
In a study reported by Syrjälä and colleagues (Syrjälä et al., 2000) older men with frequent 
falls tended to have lower amplitude motor evoked potentials in the legs when compared to older men 
without frequent falls. Although we do not know if the ‘fallers’ were frail, it is well known that frail 
older people have increased risk of falls (de Vries et al., 2013). Lower amplitude motor evoked 
potentials in frequent fallers could have been explained by smaller MUs, although that possibility was 
not investigated by Syrjälä and colleagues (Syrjälä et al., 2000).   
The main strength of the present study is that this study is the first to relate the 
electrophysiological measurements, CMAP and MUP sizes, to the presence of frailty. We studied frail 
and pre-frail men alongside robust men using advanced recently developed techniques for 
electrophysiological characterisation of MUs. Although the sample size may be considered small in 
comparison to epidemiological studies of frailty, it is large for this type of detailed physiological 
profiling. A main limitation is the cross-sectional study design which prevents conclusions about 
causality. Secondly, 25% of the men who agreed to participate in the study did not have complete data 
on frailty status and were excluded from this analysis. This issue highlights some of the difficulties 
encountered when studying frail elderly participants (unable or declining to participate in all elements 
of a research programme). However, as we have shown, those excluded from analysis did not differ 
from those included in the analysis and we expect that the data presented here are representative of 
older men in the UK. Thirdly, we used DXA-measured low muscle mass rather than unintentional 
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weight loss in the frailty phenotype. We took this action because DXA-measured low muscle mass 
can be more directly measured; it is more relevant to our study and is more likely to be chronic rather 
than a feature of recent illness. We consider this to be a significant improvement on the original 
criteria but this approach to classifying frailty has not been validated and therefore may be considered 
a limitation. However, in the absence of consensus regarding measurement of frailty, we believe that 
our frailty phenotype is a valid construct and we believe that it is more comprehensive than many 
other frailty assessment tools, often largely based only on questionnaire-derived information. Finally, 
our study was limited to men and therefore generalisability to women is unknown. 
 
Conclusion  
We have shown that older men with small CMAPs and MUPs have a higher likelihood of 
frailty and that these relationships were independent of age and BMI. These novel findings implicate 
aberrant neuromuscular structure and function involving MU remodelling to the complex frailty 
syndrome.   
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Tables 
Table 1. Clinical characteristics of the study participants 
    
Characteristics mean (SD)/ n(%) 
N 86 
Age, years 74 (5) 
BMI, kg/m2 26.1 (4.1) 
Grip Strength (kg) 37.7 (8.1) 
Current smoker, n (%) 4 (5) 
Alcohol excess (≥14 unit/week), n (%) 31 (39) 
Respiratory disease, n (%) 14 (16) 
Cardiovascular disease, n (%) 19 (22) 
Diabetes, n (%) 12 (14) 
Osteo-/Rheumatoid arthritis, n (%) 28 (33) 
Taking ≥3 medications, n (%) 41 (52) 
Frailty index 0.18 (0.17) 
Frailty phenotype:                                                                       
robust 
28 (33) 
 prefrail 40 (47) 
                                                                                                  frail 18 (21) 
Sarcopenia, n (%) 48 (56) 
Exhaustion, n (%) 15 (17) 
Low activity, n (%) 18 (21) 
Weakness, n (%) 19 (22) 
Slowness, n (%) 18 (21) 
MUP area, μV .ms 1445 (706) 
CMAP amplitude, μV 6947 (2782) 
Data are displayed as mean (SD) or n (%).  
BMI, body mass index; CMAP, compound muscle action potential; MUP, motor unit 
potential; 
N, number   
 
  
 This article is protected by copyright. All rights reserved. 
Table 2. Clinical characteristics of the study participants stratified according to tertiles of MUP and CMAP in 
vastus lateralis. 
  T1 MUP T2 MUP T3 MUP p-value   T1 CMAP T2  CMAP T3 CMAP p-value 
N 25 25 24   27 26 26  
Age, years 76±6 71±5.0a 73±6.0 0.006  78±7 72±5a 71±4a <.001 
BMI, kg/m2 26.8±3.8 26.2±5.1 24.4±2.8a 0.123   28.3±4.4 24.9±3.5a 24.4±3.0a <.001 
Smoking, n (%) 3 (12%) 0 0 0.047   2 (7%) 1 (4%) 1 (4%) 0.791 
Frequent Alcohol, n (%) 8 (36%) 8 (37%) 9 (41%) 0.949    8 (31%) 9 (41%) 11 (44%) 0.597 
Diabetes, n (%) 5 (20%) 2 (8%) 1 (4%) 0.081   9 (33%) 1 (4%) 0 <.001 
Cardiovascular disease, n (%) 9 (36%) 4 (16%) 2 (8%) 0.044   14 (52%) 3 (12%) 0 <.001 
CMAP, compound muscle action potential; MUP, motor unit potential;  T, tertile 
a the value significantly different to T1 value 
Following Bonferroni correction for multiple group comparisons, significant p value set at ≤ 0.017 
 
 
Table 3. Unadjusted and multivariable-adjusted cross-sectional relationships of motor unit characteristics with frailty 
measures 
                
Predictor Model and covariates 
Frailty index Frailty phenotype 
β 95% CI p-value OR 95% CI p-value 
                
MUP Size 1. Unadjusted -0.15 -0.23, -0.07 <.001 0.83 0.67, 1.02 0.071 
  2. BMI -0.13 -0.20, -0.05 0.002 0.82 0.66, 1.02 0.081 
  3. BMI + Age -0.10 -0.18, -0.02 0.013 0.82 0.65, 1.03 0.095 
                
                
CMAP Size 1. Unadjusted -0.57 -0.74, -0.40 <.001 0.40 0.21, 0.74 0.003 
  2. BMI -0.51 -0.70, -0.33 <.001 0.34 0.17, 0.68 0.002 
  3. BMI + Age -0.40 -0.61, -0.20 <.001 0.43 0.21, 0.90 0.026 
Negative β means that the 1SD increase in predictor is associated with improvement of frailty status, whereas positive β means that the predictor is 
associated with worsening of frailty status. An OR <1 means that a 1SD higher value of the predictor is associated with a lower risk of prefrailty or frailty 
whereas an OR >1 means that a 1SD higher value of the predictor is associated with a higher risk of prefrailty or frailty 
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Table 4.  Relative risk of prefrailty or frailty in relation to a 1 SD higher level MUP or CMAP compared to robust 
participants 
                    
Predictor Model and covariates 
      Frailty Phenotype   
    
Prefrail 
      
Frail 
  
                
      RRR 95% CI p-value   RRR 95% CI p-value 
                    
VL MUP  Unadjusted   0.91 0.74, 1.13 0.398   0.44 0.26, 0.76 0.003 
   + BMI   0.90 0.72, 1.13 0.371   0.44 0.25, 0.77 0.004 
   + Age   0.91 0.72, 1.13 0.392   0.52 0.31, 0.87 0.014 
  + Diabetes   0.91 0.74, 1.14 0.426   0.48 0.27, 0.82 0.008 
                    
VL CMAP  Unadjusted   0.50 0.26, 0.97 0.041   0.17 0.07, 0.42 <0.001 
   + BMI   0.43 0.21, 0.89 0.023   0.15 0.05, 0.40 <0.001 
   + Age   0.59 0.29, 1.20 0.146   0.28 0.11, 0.73 0.010 
  + Diabetes   0.52 0.26, 1.05 0.069   0.19 0.07, 0.50 0.001 
RRR - relative risk ratio. A significant RRR <1 for frail means that a 1SD higher value in the predictor is associated with a lower risk of frailty compared to the 
robust group. A significant RRR <1 for prefrail means that a 1SD higher value in the predictor is associated with a lower risk of prefrailty compared to the 
robust group. 
 
 
 
Table 5. Motor unit characteristics and frailty index across frailty phenotype categories 
Parameter 
    Frailty status     
  Robust Prefrail Frail  p value 
N   28 40 18   
VL CMAP, mV   8301.6±2199.1 7006.8±2607.4 4360.3±2435.8ab <.001 
VL MUP, ms/mV   1645.5±514.7 1491.4±802.6 907.4±525.2ab <.001 
Frailty Index   0.08±0.11 0.15±0.11 0.39±0.16ab <.001 
a significantly different compared to robust; b, significantly different compared to prefrail 
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Figure 1. Representative images of A) CMAP and B) MUP. CMAP negative peak amplitudes displayed here; 
robust 8632 = μV, pre-frail = 7112 μV, frail = 4215 μV. MUP areas displayed here; robust = 1632 μV.ms, pre-
frail = 1471 μV.ms, frail = 915 μV.ms. Numbers indicate; 1 MUP onset, 2 negative peak, 3 positive peak, 4 
MUP end. 
